<DOC>
	<DOCNO>NCT03022500</DOCNO>
	<brief_summary>To understand efficacy Durvalumab ( MEDI4736 ) + Tremelimumab Metastatic/relapsed pulmonary sarcomatoid carcinoma</brief_summary>
	<brief_title>Pulmonary sarcomatoid_MEDI4736+Treme</brief_title>
	<detailed_description>This phase II multi-center , open-label study evaluate efficacy safety durvalumab + tremelimumab combination treatment patient pulmonary sarcomatoid carcinoma</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>1 . Age ≥ 20 year 2 . ECOG PS ≤1 3 . Patients histologically confirm NSCLC histology sarcomatoid carcinoma ( WHO criteria sarcomatoid carcinoma use ; Carcinoma spindle and/or giant cell , Pleomorphic carcinoma , Spindle cell carcinoma , Giant cell carcinoma , Carcinosarcoma , pulmonary blastoma . If NSCLC patient show sarcomatoid carcinoma histology rebiopsy sample ( call epithelialmesenchymal transition ( EMT ) phenomenon ) , patient eligible ) 4 . Initial metastatic case recurrent case curative treatment ( chemotherapy line allow ) 5 . A patient least one measurable lesion diameter confirm ≥ 10mm spiral CT multidetector CT ( MD CT ) , ≥ 20 mm conventional CT ( use consistent method study period ) . 6 . If patient brain metastasis neurological symptom , stabilize neurologically prior radiotherapy surgery brain metastasis ( neurologic symptom progress without steroid treatment ) 7 . Adequate hematologic ( neutrophil count ≥ 1,500 cells/mm3 , platelet ≥ 100,000 cells/mm3 ) , hepatic ( transaminase ≤ upper normal limit ( UNL ) x2.5 , bilirubin level ≤ UNLx1.5 ) , renal ( creatinine ≤ UNL ) function 8 . A patient willingness comply study protocol study period capable complying . 9 . A patient sign informed consent prior participation study understand he/she right withdrawal participation study time without disadvantage Absolute neutrophil count 1,500 cells/mm3 , platelets 100,000 cells/mm3 10 . Expected survival ≥ 3 month 11 . Female subject must either nonreproductive potential ( ie , postmenopausal history : ≥60 year old menses ≥1 year without alternative medical cause ; history hysterectomy , history bilateral tubal ligation , history bilateral oophorectomy ) must negative serum pregnancy test upon study entry . 1 . A patient measurable disease 2. chronic systemic steroid therapy form immunosuppressive medication 3. receive livevirus vaccination within 30 day plan treatment start 4. history diverticulitis , intraabdominal abscess , gastrointestinal ( GI ) obstruction , abdominal carcinomatosis know risk factor bowel perforation 5. active symptomatic central nervous system ( CNS ) metastases and/or carcinomatous meningitis 6. severe hypersensitivity reaction treatment another monoclonal antibody ( mAb ) 7. active autoimmune disease within past 2 year ( NOTE : Subjects vitiligo , Grave 's disease , psoriasis require systemic treatment within past 2 year exclude ) document history autoimmune disease syndrome require systemic steroid immunosuppressive agent 8. prior treatment antiprogrammed cell death protein1 ( antiPD1 ) , PD Ligand1 ( PDL1 ) PD Ligand2 ( PDL2 ) agent anti CTLA4 agent ( include durvalumab tremelimumab ) 9. active infection require therapy 10. history Human Immunodeficiency Virus ( HIV ) 11. active Hepatitis B C ( inactive healthy carrier HBV appropriate prophylactic antiviral agent allow ) 12. symptomatic ascites pleural effusion 13. pneumonitis require course oral steroid assist recovery , history interstitial lung disease 14. pregnant breastfeeding , expect conceive father child within project duration study 15 . History active tuberculosis 16 . History allogeneic organ transplant . Current prior use immunosuppressive medication within 28 day first dose durvalumab tremelimumab , exception intranasal inhaled corticosteroid systemic corticosteroid physiological dos , exceed 10 mg/day prednisone , equivalent corticosteroid 17 . Receipt last dose anticancer therapy ( chemotherapy , immunotherapy , endocrine therapy , target therapy , biologic therapy , tumor embolization , monoclonal antibody , investigational agent ) ≤ 21 day prior first dose study drug 18 . History allogeneic organ transplant 19 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , uncontrolled hypertension , unstable angina pectoris , cardiac arrhythmia , active peptic ulcer disease gastritis , active bleeding diatheses include subject know evidence acute chronic hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) , psychiatric illness/social situation would limit compliance study requirement compromise ability subject give write informed consent 20 . Female patient pregnant breastfeed male female patient reproductive potential willing employ effective birth control screen 180 day last dose durvalumab + tremelimumab combination therapy 90 day last dose durvalumab monotherapy , whichever long time period</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>